China / National Reimbursement Drug List (NRDL) 2020: What Reward for Innovation?
Eric Bouteiller examines the most recent update to China’s National Reimbursement Drug List, the positive impact…
The EFPIA’s Nathalie Moll outlines the significance of Europe’s Beating Cancer Plan to cancer patients in Europe, and its potential to boost the continent’s push to catch up with the…
Eric Bouteiller examines the most recent update to China’s National Reimbursement Drug List, the positive impact…
On 25 November 2020, the European Commission adopted a Pharmaceutical Strategy for Europe with the stated aim of…
David H. Crean, managing director for Objective Capital Partners, provides insights on US innovation and long term…
In a wide-ranging interview, Henrik Asmussen outlines his priorities for Amgen’s important Swiss affiliate, market access and pricing challenges, the company’s exciting pipeline, and what makes Amgen Switzerland a great place to work. I was told when I came that Switzerland is a safe haven with easy access. What I experienced was something entirely different Can you begin by…
In a recent article for PharmaBoardroom, Objective Capital’s David Crean took a look at the state of US…
David H. Crean, managing director for Objective Capital Partners, provides insights on US innovation and long term…
Patient groups oftentimes serve as the authority on a specific disease when it comes to advancing research.…
The South Korean government has designated the promotion of artificial intelligence (AI)-based drug development and…
Nares Damrongchai has been the CEO of the Thailand Center of Excellence for Life Science (TCELS) since its…
Johnson & Johnson’s network of healthcare innovation incubators, JLABS, opened its doors in Shanghai in June…
Dr Valters Bolevics, director general of the Association of International Research-based Pharmaceuticals…
The UAE’s distinctive willingness to embrace innovation and the ‘can-do’ spirit of authorities marks the…
In the coming years, Turkey plans to prioritize R&D initiatives, health studies and medical innovation:…
Merck KGaA has moved to continuously expand its manufacturing capacity and capability in recent years with a number…
Some of the key stakeholders in Swedish healthcare and life sciences outline why they feel Sweden’s capital,…
The Greater Bay Area’s – and in particular, Shenzhen’s – prowess in life sciences manufacturing…
On 21 September 2019, the China Pharmaceutical International Innovation and Research Development Association…
Despite lacking a national champion to bolster its innovative eco-system since the 2007 acquisition of Organon by…
Austria has long been merely a cog in the wheel of global R&D, lying in the shadows of neighboring research…
The second edition of the European Cancer Forum was held in Brussels, Belgium on Tuesday, 29 January 2020. Hosted…
With its brand new hub in Shanghai dedicated to research, business development and venture funding, German pharma…
Guangdong province and neighbouring Hong Kong have long been fundamental to China’s metamorphosis into an…
Hungary operates under a state-owned universal National Health Insurance Fund (OEP), completely financed through…
Eric Bouteiller examines the most recent update to China’s National Reimbursement Drug List, the positive impact…
A new regulation is helping Portugal’s market access conditions for pharmaceuticals catch up with those of other…
While drug developers, healthcare practitioners and patients all rejoice at the advent of a golden age of…
In PharmaBoardroom’s first coverage of Portugal in 2007, generics represented 16 percent of the country’s…
Dr Neil Cashman looks at the potential impact of US FDA approval for Biogen’s aducanumab on the search for…
Kenichi Tamiya, director for Biomedical Policy at the Kobe City Government and managing director of the Kobe…
Professor Jackie Hunter looks at why the pharmaceutical industry has been so slow to adopt artificial…
“If you look at the cuts in the public sector, the science budget has been relatively lightly touched. This sends…
Tom Achoki of Mass Sciences explores the possibilities that better access to high-quality real-world data will…
PharmaBoardroom’s latest country report gives an up-to-date and comprehensive overview of one of the most…
David H. Crean, managing director for Objective Capital Partners, provides insights on US innovation and long term…